Thiopurines promote Epstein-Barr virus-related lymphomas, nonmelanoma skin cancers and acute myeloid leukemias. Anti-tumor necrosis factor (anti-TNF) agents may inhibit or activate carcinogenesis according to the cellular pathways that are activated. A mild increase in the risk of melanoma has been reported in patients exposed to anti-TNF agents. Transplanted patients with previous history of cancer are at high risk of cancer recurrence when receiving posttransplant immunosuppressive therapy, particularly within the first 2 years of treatment. Few data exist for patients with chronic inflammatory disease. In the CESAME cohort that included essentially patients receiving thiopurines, there was no excess incidence of recurrent or new cancer associated with exposure to immunosuppressive therapy in the patients with previous cancer at cohort entry. In clinical practice, the decision to start or resume immunosuppressive therapy in inflammatory bowel disease (IBD) patients with recent cancer should be discussed case by case with cancer specialists. However, taken into account the experience of transplant specialists, it could be suggested not to consider a waiting period for women with adequately treated uterine high-grade cervical dysplasia. For invasive cancers, a waiting period of 2 years should be considered if possible. During this period, treatment of IBD should be restricted to 5-aminosalicylic acid, steroids, nutritional therapy, or surgery, except in case of aggressive IBD that cannot be controlled by these methods. A longer waiting period of 5 years could be recommended for the most aggressive forms of cancers, such as melanomas, aggressive breast cancers, sarcomas, urinary tract cancers, and myelomas.

Keywords:
Second cancer, Immunosuppressive therapy, Biologics, Cancer recurrence
1.
Charpentier C, Salleron J, Savoye G, et al: Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2013, E-pub ahead of print.
2.
Elandt K, Aletaha D: Treating rheumatic patients with a malignancy. Arthritis Res Ther 2011;13:223.
3.
Gutierrez-Dalmau A, Campistol JM: Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007;67:1167-1198.
4.
Zitvogel L, Tesniere A, Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-727.
5.
Munz C, Moormann A: Immune escape by Epstein-Barr virus associated malignancies. Semin Cancer Biol 2008;18:381-387.
6.
Jensen AO, Thomsen HF, Engebjerg MC, et al: Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009;100:200-205.
7.
Sokol H, Beaugerie L: Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009;58:1427-1436.
8.
Beaugerie L, Brousse N, Bouvier AM, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-1625.
9.
Kane S: Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1158-1160.
10.
Offman J, Opelz G, Doehler B, et al: Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004;104:822-828.
11.
Perrett CM, Walker SL, O'Donovan P, et al: Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008;159:198-204.
12.
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al: Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-1628.e5.
13.
Kamel OW, van de Rijn M, Weiss LM, et al: Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-1321.
14.
Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-3915.
15.
Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010;140:883-899.
16.
Mariette X, Matucci-Cerinic M, Pavelka K, et al: Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-1904.
17.
Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F: Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012;143:382-389.
18.
Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD: Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-399.e1.
19.
Beaugerie L, Svrcek M, Seksik P, et al: Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013;145:166-175.e8.
20.
Huang E, Buchholz TA, Meric F, et al: Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer 2002;95:2059-2067.
21.
Curtis RE, Freedman M, Ron E, et al: New malignancies among cancer survivors: SEER cancer registries, 1993-2000. National Cancer Institute, NIH Publ No 05-5302. Bethesda, 2006.
22.
Reinisch W, Panes J, Lemann M, et al: A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008;103:2284-2292.
23.
Penn I: The effect of immunosuppression on pre-existing cancers. Transplantation 1993;55:742-747.
24.
Penn I: Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997;2:14-17.
25.
Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP: Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010;62:755-763.
26.
Strangfeld A, Hierse F, Rau R, et al: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
27.
Conraads VM, Denollet J, Vorlat A, Moulijn AC, Vrints CJ: Screening for solid organ malignancies prior to heart transplantation. Transplantation 2001;71:1481-1483.
28.
Serrate C, Silva-Moreno M, Dartigues P, et al: Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. Inflamm Bowel Dis 2009;15:1449-1451.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.